LLY vs GILD
By Alex · Tickerpine
Eli Lilly and Company vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | GILD |
|---|---|---|
| Price | $1,233.66 | $148.77 |
| Market cap | $1.10T | $184.47B |
| P/E ratio | 41.8 | — |
| ROE | 102.29% | -20.68% |
| Profit margin | 33.53% | -10.64% |
| Revenue growth | 47.70% | 10.20% |
| Dividend yield | 0.55% | 2.20% |
| Beta | 0.51 | 0.34 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs GILD in plain English
- LLY is the bigger company — about 6.0× the market cap of GILD.
- LLY earns a higher return on equity (102% vs -21%).
- LLY is growing revenue faster (48% vs 10%).
- GILD has the higher dividend yield (2.20% vs 0.55%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.